A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Trial Profile

A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs RGX 314 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors REGENXBIO
  • Most Recent Events

    • 08 Nov 2017 According to a REGENXBIO media release, following a scheduled review by an independent Data Safety and Monitoring Board (DSMB), the Company expects to initiate dosing of the third cohort in the Phase I clinical trial by the first quarter of 2018.
    • 08 Nov 2017 According to a REGENXBIO media release, dosing of second cohort has been completed. A total of 12 patients, from four different sites, have now been treated in the trial.
    • 20 Sep 2017 According to a REGENXBIO media release, the company plans to share an interim trial update by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top